Radiolabeled Luminol Imaging Agents for Non-Invasive ROS Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective, non-invasive methods for monitoring and imaging oxidative stress at the molecular level, which is implicated in various diseases such as cardiovascular disease, diabetes, and cancer, limiting diagnostic and therapeutic strategies.
Innovation Solution
Development of imaging agents comprising a luminol component, a chelator, and a radiolabel component, such as 68Ga, to detect reactive oxygen species (ROS) using PET and SPECT, allowing for sensitive and specific detection of superoxide and hydrogen peroxide generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used, then general anatomical imaging is achieved, but molecular-level detection of oxidative stress is not possible
Solution Approach 1:
The imaging agent is divided into distinct functional segments: a luminol component for ROS detection, a chelator for radiometal binding, and a linker group connecting them. This segmentation allows each component to perform its specific function optimally while enabling modular design and synthesis of the overall imaging agent.
Solution Approach 2:
The imaging agent combines multiple material components with different properties into a single composite molecule. The luminol component provides chemiluminescent/fluorescent activity for ROS detection, the chelator provides radiometal coordination capability, and the linker provides structural connection. This composite structure enables simultaneous detection capabilities that neither component could achieve alone.
2Measurement precision
If imaging agents with high ROS sensitivity are developed, then detection precision improves, but the complexity of the imaging agent increases
Solution Approach 1:
The imaging agent is designed to perform multiple functions within a single molecule: detecting reactive oxygen species through the luminol component, providing signal amplification through radiometal labeling, and enabling both optical and nuclear imaging modalities. This multi-functionality reduces the need for multiple separate agents while maintaining high detection precision.
3Object-affected harmful factors
If non-invasive imaging methods are used, then patient safety is improved, but the ability to monitor oxidative stress at molecular level is limited
Solution Approach 1:
The patent replaces invasive mechanical or surgical measurement methods with non-invasive nuclear medicine imaging techniques. The radiolabeled imaging agent allows detection of oxidative stress through external imaging devices (PET/SPECT scanners) without requiring tissue biopsy or other invasive procedures, thereby eliminating mechanical intrusion while maintaining molecular-level detection precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The imaging agents provide 4-fold higher uptake and stable retention in affected tissues, correlating with ROS activity and oxidative stress, enabling non-invasive monitoring and potential therapeutic evaluation.
Implementation Method 1
a radiolabel component (e.g., 68Ga) bound to or within the chelator. The imaging agent described herein is capable of monitoring, targeting, or imaging oxidative stress
Implementation Method 2
using, for example, positron emission tomography or single photon emission computed tomography
Implementation Method 3
The imaging agent comprises a luminol component comprising a luminol moiety or functional analogue thereof
Implementation Method 4
capable of monitoring, targeting, or imaging oxidative stress, reactive oxygen species (ROS), superoxide generation, or hydrogen peroxide generation
Data Source
AI summary
The present disclosure provides for imaging agents and methods of making and using the same. The imaging agent comprises a luminol component comprising a luminol moiety or functional analogue thereof; a chelator; a linker group bonding or complexing the luminol component to the chelator; and a radiolabel component bound to the chelator. The imaging agent described herein is capable of monitoring, targeting, or imaging oxidative stress, reactive oxygen species (ROS), superoxide generation, or hydrogen peroxide generation, mediating pathophysiology of different disease states.